Recruitment unclearEUCTR 2018-003252-20
A 52-Week Open-Label Extension Study of Pimavanserin in Subjects With Major Depressive Disorder and Inadequate Response to Antidepressant Treatment
This historical record does not confirm current site availability.
Historical research recordMultiple countriesDepression
Understand this study
What is this study about?
This EU register entry describes an interventional medicine trial, designed to assign participants a study treatment. The protocol sets out the treatment, eligibility criteria and assessments. Check the source details below for country statuses and any transfer to CTIS.
Who could participate?
This study is for people with depression. Other eligibility criteria apply.
- Listed locations
- Finland · Poland and 2 more locations
- Study phase
- Phase 3Usually a larger study designed to confirm effectiveness and safety in a broader group.
What to know before participating
A point to clarify
This is historical registry information. What is the current study status and protocol?
Things to check before joining
Study start dateNot clearly listed
- Recruitment status
- Recruitment unclear
- Enrollment listed in the registry
- 420
- Sponsor
- ACADIA Pharmaceuticals Inc
- Sponsor type
- Other organization
- Study type
- Drug
- Intervention type
- Medication / drug
- Study phase
- Phase 3Usually a larger study designed to confirm effectiveness and safety in a broader group.
- Locations
- United Kingdom, Finland, Poland, ...
- Age range
- Not clearly listed
- Official registry ID
- EUCTR 2018-003252-20
- Official title
Show the full official title
A 52-Week Open-Label Extension Study of Pimavanserin in Subjects With Major Depressive Disorder and Inadequate Response to Antidepressant Treatment
Recruitment & locations
Status unknownFinland · Poland · Slovakia
1 more locations
- United Kingdom
Registry details
Historical country statuses
- Finland — Prematurely Ended
- United Kingdom — GB - no longer in EU/EEA
- Poland — Prematurely Ended
- Slovakia — Prematurely Ended
A listed location does not confirm current availability.
Questions about this study
Who is behind this study?
The study sponsor is ACADIA Pharmaceuticals Inc.
Who can participate?
This study is for people with depression. Other eligibility criteria apply.
Want to explore more studies?
Explore studiesRelated studies
A Double-Blind, Randomized, Parallel-Group Study with Quetiapine Extended Release as Comparator to Evaluate the Efficacy and Safety of Seltorexant 20 mg as Adjunctive Therapy to Antidepressants in ...
A Double-blind, Randomized, Placebo-controlled, Multicentre, Relapse-prevention Study of Vortioxetine in Paediatric Patients Aged 7 to 11 Years With Major Depressive Disorder